Should I Buy CNTX? CNTX 2026 Analysis

Should You Buy Context Therapeutics Inc (CNTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.280

1 Day change

0.88%

52 Week Range

2.850

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: price is still in a short-term overbought/extended zone (RSI ~71) and momentum is losing steam (MACD histogram positive but contracting) while the stock is down sharply today.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
If you must act immediately, this is more of a speculative hold/watch than a chase-buy; a cleaner entry would be nearer the pivot/support area (~~2.18) with room toward S1 (~~1.68) if selling pressure continues.
Medium-term upside case remains tied to clinical progress, but near-term setup does not justify an aggressive buy at 2.26 after a -7.69% regular-session drop.

Technical Analysis

Trend (moving averages): Bullish with SMA_5 > SMA_20 > SMA_200, indicating the broader trend is still up.
Momentum (MACD): MACD histogram is above 0 (0.0696) but positively contracting, suggesting upside momentum is fading.
RSI: RSI_6 at 71.38 indicates a near-term overbought/extended condition (despite the provided label), increasing pullback risk.
Key levels: Pivot 2.184 (current 2.26 is only slightly above); Resistance 2.692 then 3.006; Support 1.676 then 1.362.
Near-term pattern odds (provided): Bias remains positive (projected +1.65% next day, +3.15% next week, +11.25% next month), but today’s sharp drop suggests choppier execution risk in the very near term.

Positive Catalysts

citing encouraging clinical activity (partial response in Cohort 3 for platinum-resistant ovarian cancer).
on 2026-02-11 (After Hours) can act as a volatility/catalyst window.

Neutral/Negative Catalysts

plus contracting MACD increases risk of further mean reversion toward 2.18 or lower supports.

Financial Performance

Latest quarter: 2025/Q3
Revenue: 0 (still pre-commercial; no meaningful YoY improvement).
Net income: -9.69M, down 44.48% YoY (loss widened).
EPS: -0.10, down 54.55% YoY.
Takeaway: Financials show increasing losses with no revenue base yet; valuation and direction depend mainly on pipeline progress rather than operating growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Most recent update (2025-11-06): H.C. Wainwright reiterated Buy and raised price target to $5 from $4 after Q3.
Wall Street pro view (pros): Clinical signal noted (partial response in a difficult indication) supports upside optionality if data strengthens.
Wall Street pro view (cons): Single-firm coverage in the provided data and pre-revenue losses mean conviction is highly data-dependent; absent new catalysts, the stock can retrace quickly.
Influential/political trading: No recent congress trading data available; hedge funds/insiders shown as neutral with no significant recent trend.

5 Analyst Rating

Wall Street analysts forecast CNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTX is 5.25 USD with a low forecast of 4 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.260

Low

Averages

5.25

High

Current: 2.260

Low

Averages

5.25

High

H.C. Wainwright

Buy

maintain

$4 -> $5

AI Analysis

2025-11-06

Reason

H.C. Wainwright

Price Target

$4 -> $5

AI Analysis

2025-11-06

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Context Therapeutics to $5 from $4 and keeps a Buy rating on the shares following the Q3 report. The company noted a confirmed partial response in Cohort 3 for a patient with platinum resistant ovarian cancer, which is a "highly positive sign of activity," the analyst tells investors in a research note.

Guggenheim

Buy

initiated

2025-09-17

Reason

Guggenheim

Price Target

2025-09-17

initiated

Buy

Reason

Guggenheim initiated coverage of Context Therapeutics with a Buy rating and $5 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNTX

Unlock Now

CNTX Should I Buy

CNTX Should I Buy

Should You Buy Context Therapeutics Inc (CNTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch